148results about How to "Promote phagocytosis" patented technology

The invention discloses an oil-in-water emulsion free of surfactant. The emulsion comprises a metabolizable oil phase, a water phase and oil-water amphipathic solid particles dispersed in the water phase and having biocompatibility, wherein the oil phase comprises squalene or / and tocol; the water phase is any one or a combination of at least two of purified water, water for injection, aqueous liquid of glycerol, buffered saline liquid and clinically available infusion liquid; and the average grain diameter of the solid particles is at nanometer-to-micron grade. The emulsion can be used as a vaccine adjuvant or a medicine delivery or controlled release carrier; the properties of the emulsion can be controlled and regulated; the obtained emulsion is stable; the use of a surfactant is avoided; and harm to the human body and pollution on the environmental can be reduced.

The invention relates to milk and a method for preparing thereof, in particular to fluid milk applicable for infants below six months old, which belongs to a milk technical field. The milk comprises 18.5-33 percent of fresh milk or reconstituted milk, 0.8-1.6 percent of concentrated lactoalbumin, 3.1-8.5 percent of sugar, 0.35-2.5 percent of vegetable oil, 0.01-0.6 percent of emulsifier (0.1-0.4 percent is preferable), 3-10 mg / 100g of ethylamine sulfonic acid, 1-7mg / 100 g of nucleotide, 20-30mg / 100 g of casein phospho peptides, 1-21mg / 100 g of DHA, 4-30mg / 100 g of ARA, 4-15mg / 100 g of lactoferrin, 50-70mg / 100g of GOS, 40-60mg / 100 g of FOS, 5-28mg / 100 g of choline, 5-28mg / 100 g of phaseomannite, 0.007-0.03 percent of Vitamin B complex, 0.00005-0.08 percent of complex mineral element (by elements) and soft water for the rest percentage.

The invention relates to milk and a method for preparing thereof, in particular to fluid milk applicable for infants of 12-36 months old, which belongs to a milk technical field. The milk comprises 5.5-16 percent of full-cream milk powder, 0.12-3.3 percent of dried skimmed milk, 0.065-7.26 percent of sugar, 0.35-2.5 percent of vegetable oil, 0.01-0.6 percent of emulsifier, 3-10mg / 100 g of ethylamine sulfonic acid, 1-12mg / 100 g of nucleotide, 20-30mg / 100 g of casein phospho peptides, 0.3-10mg / 100g of DHA, 0.6-22mg / 100g of ARA, 4-15mg / 100g of lactoferrin, 20-130mg / 100g of GOS, 30-500mg / 100g of FOS, 5-35mg / 100g of choline, 3-28mg / 100g of phaseomannite, 0.007-0.08 percent of Vitamin B complex, 0.00005-0.08 percent of complex mineral element (by elements) and water for the rest percentage.

Techniques for treating a tumor and vaccinating against cancer are described. The techniques include treating the tumor by positioning electrodes over an interface between the tumor and non-tumor tissue and applying sub-microsecond pulsed electric fields. The positioning is facilitated by an imaginary contour line of a threshold value of the electric field. In an example, the imaginary contour line is overlaid over images that include the tumor such that the electrodes are properly positioned over the tumor. The techniques also include vaccinating against cancer by passing sub-microsecond pulsed electric fields through tumor cells of a subject sufficient to cause the tumor cells to express calreticulin on surface membranes. The tumor cells are extracted and introduced with the expressed calreticulin into the subject or another subject, thereby providing a vaccination.

The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species. The present invention further contemplates a method for the prophylaxis or treatment of mammalian, animal or avian subjects for inflammatory conditions including chronic or transitory inflammatory conditions or for ameliorating. the symptoms of an inflammatory condition by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Euphorbiaceae family or botanical or horticultural relatives thereof or a derivative, chemical analogue or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or be in the form of a chemical fraction, sub-fraction or preparation or extract of the plant.

The invention relates to a pH-sensitive anticancer prodrug and a preparation method as well as application thereof, which belongs to the field of medicine and chemical industry. The technical problem to be solved is to provide the pH-sensitive anticancer prodrug, and the anticancer prodrug has highest solubility when the pH value is between 4 and 6, can nearly not be dissolved when the pH value is less than 3 or more than 7, and almost does not release adriamycin during the circulation due to small solubility particularly when circulating in blood (the pH value is approximately equal to 7.4), thereby having small toxic side effect. The pH-sensitive anticancer prodrug is a conjugate obtained by coupling the adriamycin and pectin with a molecular weight of between 71,000 and 400,000 through a chemical bond. The pH-sensitive anticancer prodrug is obtained by the following steps: a pectin aqueous solution and an adriamycin aqueous solution are added with a dehydrating agent to react under the condition that the pH value is between 6 and 8, and then are dialyzed and condensed.

The invention discloses an amphiphilic camptothecin polymer prodrug taking phenylboronic acid ester as a connecting unit and a co-delivery micelle system thereof. A polyethylene glycol-polyglutamate camptothecin two-block polymer (mPEG-BC-PGluCPT) is synthesized by taking catechol phenylborate (BC) as a connecting unit, and then a doxorubicin loaded micelle (mPEG-BC@PGluCPT.Dox) of the polymer isconstructed. Aiming at the poor water solubility of camptothecin, a polymer prodrug using camptothecin as a hydrophobic end by modifying 20 sites of hydroxyl groups of camptothecin is synthesized, which can effectively promote the assembly of the two-block polymer into a micelle. The solubility of camptothecin is improved, the stability of a camptothecin lactone ring is increased, and the curativeeffect and bioavailability are improved in order to overcome limitations of clinical treatment of camptothecin. The amphiphilic camptothecin polymer prodrug prepared by the method provided by the invention can be used for constructing a nano drug common delivery system, and has good drug release property, strong cell inhibition rate and good cell phagocytosis.

The invention discloses a C-type agglutinin gene of procambarus clarkia as well as a preparation method and applications thereof. The method comprises the following steps: A. extracting total RNA (ribose nucleic acid); B. synthetizing a first chain cDNA; C. acquiring partial nucleotide sequences; D. acquiring the nucleotide sequences at 3'-RACE: 3' end; E. acquiring the nucleotide sequences at 5'-RACE: 5' end; F. acquiring the complete nucleotide sequences of the gene; and G. coding an amino acid sequence of protein by the C-type agglutinin gene. From the cloning in procambarus clarkia to theC-type agglutinin gene, the gene is cloned to a PET-28a carrier, recombinant protein mClec is expressed in colon bacillus BL21 (DE3), and the purified mClec expresses agglutination effect to multiplebacteria and rabbit red blood cells; and the protein mClec or recombinant agglutinin obtained from cloning prokaryotic expression vector on the agglutinin gene can be used for producing shrimp and fish antivirus and antibacterial medicaments.

The invention discloses a diblock polymer with benzeneboronic acid ester as the connecting unit. Benzeneboronic acid catechol ester (BC) is adopted as the connecting unit to synthesize PEG-BC-PBLG diblock polymer so as to construct doxorubicin loaded micelle (PEG-BC@PBLG.Dox). The invention also discloses a preparation method of the diblock polymer, and the method includes: (1) preparing the dopa derivative PEG-3, 4-DA of PEG-NH2; (2) subjecting PEG-3, 4-DA and 3-aminophenylboronic acid to dehydration condensation so as to synthesize the benzeneboronic acid ester derivative PEG-BC of PEG; and (3) using PEG-BC to perform ring opening on 5-benzyl ester-L-glutamic acid-N-carboxyanhydride (BLG-NCA), thus obtaining the diblock polymer PEG-BC-PBLG with benzeneboronic acid ester as the connecting unit. The diblock polymer prepared by the method provided by the invention can be used for construction of a nano-micelle, and has the advantages of good drug release, low cytotoxicity and good cell phagocytosis.

The present invention aims at synthesizing one kind of nanometer pH sensor with embedded reference dye and sensitive dye and stable performance for non-invasive monitoring of dynamic pH variation inside cell. The preparation process includes mixing oil phase cyclohexane, surfactant Triton X-100 and co-surfactant n-hexanol and water as dispersive phase to obtain water-in-oil micro emulsion; adding mixed sensitive and reference dye liquid via stirring; adding ethyl acetate as sylylation reagent, TEOS and catalyst ammonia water to react, demulsifying with acetone, washing with absolute ethanol and super-purified water to obtain inner reference nanometer sensor with silicon shell. The inner reference nanometer sensor is used in non-invasive dynamic intracellular pH monitoring.

The invention discloses an SIRP alpha (signal regulatory protein alpha) fusion protein, a preparation method and application thereof. The fusion protein comprises a V structural domain of SIRP alpha and an Fc segment with effector function; the V structural domain comprises an amino acid sequence SEQ ID No.1; and the Fc segment comprises a constant region of human body IgG1 or IgG4 antibody. The fusion protein provided by the invention enhances the affinity of SIRP alpha and CD47, the half-life in vivo, and the Fc segment mediated effector function, and can strongly induce the phagocytosis ofmacrophages to a variety of tumor cells.

The invention provides a natural water shield drink. A preparation process of the natural water shield drink comprises the following steps of: (1) blanching and deactivating the collected water shield at 90 to 100 DEG C, then smashing and beating the deactivated water shield, and filtering to obtain water shield juice; (2) crushing astragalus root into powder and mixing the astragalus root powderwith water based on the mass ratio of 1:15 to 1:25 and then boiling and filtering the mixture to obtain astragalus root juice; and (3) mixing the water shield juice obtained in the step (1) with the astragalus root juice in the step (2) based on the mass ratio of 1:1 to 1:2, and sterilizing and then filling the mixed juice to obtain the water shield drink. The water shield drink disclosed by the invention contains no additive, is longer in shelf life, can maintain and replenish water in human body, has the efficacies of clearing away heat and toxic materials, sterilizing and diminishing inflammation and tonifying middle-Jiao and qi, and can also be used for preventing and treating anaemia, hepatitis and other diseases and intensifying the immunologic function of body.

The invention provides an active targeting type amphipathic polypeptide nano-drug carrier and preparation and application thereof, and belongs to the technical field of biological medicines. According to an amphipathic polypeptide, an alkyl chain serves as the hydrophobic end, a polypeptide chain with active targeting functional and side chain modification fluorescent functional molecules serves as the hydrophilic end, and an anti-tumor drug is wrapped in a hydrophobic cavity of a micelle formed by self-assembling the amphipathic polypeptide. The nano-carrier can actively target tumor cells and enter the tumor cells through receptor-mediated endocytosis, the amphipathic polypeptide and phospholipid molecules have strong interaction, and the phagocytosis of a nano-drug by tumor cells is promoted. In the process, tracing can be conducted through fluorescent imaging of fluorescent functional molecules modified on the polypeptide chain, and the tumor imaging aim is realized. Finally, the anti-tumor drug is slowly released to kill tumor cells and restrain the growth of tumors. The amphipathic polypeptide nano-carrier is free of toxin, high in biocompatibility and remarkable in anti-tumor efficiency, and the tumor diagnosis and treatment can be integrated.

The invention discloses a cationic angelica polysaccharide nanoparticle gene delivery system. The system is a gene delivery system of angelica polysaccharide combined DNA (Deoxyribonucleic Acid) plasmids modified by amine compounds, wherein molecular weight distribution of angelica polysaccharides is 30 to 50KD and 80 to 100KD; the mass ratio of the cationic angelica polysaccharide to the DNA plasmids is (1-200):1; and the particle diameter of the cationic angelica polysaccharide-DNA plasmid nancomposite is 21 to 77nm. The system has the characteristics that: 1, the angelica polysaccharide has various biological activities such as immune regulation activity, anti-aging activity, anticoagulation activity and the like, is safe and biologically degradable, does not have immunogenicity and isprepared with a simple, economic and convenient process; and 2, all the three cationic angelica polysaccharides have good DNA plasmid combination effect and gene delivery expression effect. Positive charges carried by primary amine, secondary amine and tertiary amine groups combined with saccharide chains can be effectively combined with the DNA plasmids with negative charges through an electrostatic effect, so that the plasmids are protected from being degraded by various enzymes inside and outside cells.

The invention provides a preparation method for of a metal-doped fluorescent carbon quantum dot. The preparation method comprises the following steps: 1) dissolving a metal porphyrin compound in tetrahydrofuran to obtain liquid A; 2) dissolving a polycarboxylic acid compound in water to obtain liquid B; 3) mixing the liquid A and the liquid B and carrying out ultrasonic dispersion to obtain mixedliquid C; 4) heating the mixed liquid C in oil bath, after the mixed liquid C is viscous, adding water to continue the reaction, and repeating the process for multiple times to obtain reaction liquidD; and 5) adding water to the reaction liquid D and adjusting the pH by using an alkaline reagent, dialyzing the supernatant of the reaction liquid D, collecting the aqueous solution obtained by dialysis, and lyophilizing the aqueous solution to obtain the metal doped fluorescent carbon quantum dot. According to the preparation method, the poorly water-soluble metal porphyrin compound is coated bythe water-soluble polycarboxylic acid compound under a hydrothermal condition, so that the metal doped fluorescent carbon quantum dot is high in metal doping rate and high yield, small in toxicity and wide in application range.

The invention discloses cationized polysaccharide nanoparticle gene delivery systems, which are gene delivery systems combining polysaccharides modified by an amine compound and DNA plasmids, wherein the mass ratio of the cationized polysaccharides to the DNA plasmids is (0.5-200):1; the particle size of the cationized polysaccharide-DNA plasmid nano composites is 21 to 414 nanometers; and the amine compound is spermine, ethylenediamine or polyethyleneimine with a number-average molecular weight of 600Da to 2,000Da. The polysaccharides of traditional Chinese medicine universally have various bioactivities for immunoregulation, aging resistance, coagulation resistance and the like. Compared with other viral vector and other non-viral vector gene delivery systems, the cationized polysaccharide nanoparticle gene delivery systems are safe, free from immunogenicity and biodegradable, and the preparation process of the cationized polysaccharide nanoparticle gene delivery systems is simple and economic. The cationized polysaccharides have good DNA plasmid bonding actions and gene delivery and expression functions. The positive charges on the aminos bonded with the polysaccharide chains can effectively combine with the negative charges on the DNA plasmids to protect the plasmids from being degraded by various enzymes in and out cells.

The invention provides a gene medicine delivery system comprising a carrier and a gene medicine loaded in the carrier. The gene medicine delivery system is characterized in that the carrier is silane coupling agent-modified mesoporous silica nanoparticles; the gene medicine is stored in pore channels of the mesoporous silica nanoparticles; in the delivery system, 80-300 microgram of gene medicine is stored in 1 mg of silane coupling agent-modified mesoporous silica nanoparticles. By using the delivery system provided by the invention, the gene medicine can be protected against enzymolysis during in vivo delivery, can simultaneously escape from an endosome well and is transferred to cytoplasm.

The invention relates to milk and a method for preparing thereof, in particular to fluid milk applicable for infants of 12-36 months old, which belongs to a milk technical field. The milk comprises 5.5-16 percent of full-cream milk powder, 0.12-3.3 percent of dried skimmed milk, 0.065-7.26 percent of sugar, 0.35-2.5 percent of vegetable oil, 0.01-0.6 percent of emulsifier, 3-10mg / 100 g of ethylamine sulfonic acid, 1-12mg / 100 g of nucleotide, 20-30mg / 100 g of casein phospho peptides, 0.3-10mg / 100g of DHA, 0.6-22mg / 100g of ARA, 4-15mg / 100g of lactoferrin, 20-130mg / 100g of GOS, 30-500mg / 100g of FOS, 5-35mg / 100g of choline, 3-28mg / 100g of phaseomannite, 0.007-0.08 percent of Vitamin B complex, 0.00005-0.08 percent of complex mineral element (by elements) and water for the rest percentage.

The invention discloses an application of amino fullerenes in preparing antibacterial materials and an antibacterial material. Amino fullerenes used in this application include fullerene derivatives chemically bonded with organic amine groups on the surface of the fullerene feedstock, which are prepared by nucleophilic addition reaction of fullerenes and organic amine compounds. The amino fullerene used in the invention has good water solubility, small particle size, good dispersibility, is not easy to agglomerate, has positive charge on the surface, is easy to adsorb on the surface of the bacterial body, is easy to phagocytosis of the bacterial body, and has good free radical scavenging effect; and the amino fullerene used in the invention has good water solubility, small particle size, good dispersibility, is not easy to agglomerate, and is positively charged on the surface; At that same time, the invention has good antibacterial effect at low concentration, can achieve effective bactericidal effect without the aid of photodynamic force, can kill or inhibit gram-positive bacteria, gram-negative bacteria or fungi, can selectively kill or inhibit bacteria, has no toxicity to cells,and can be use for preparing antibacterial materials.

The invention discloses a recombinant yeast Kluyveromyces for expressing antibodies or antibody analogues and application thereof. The invention provides a method for constructing the recombinant yeast Kluyveromyces for expressign antibodies or antibody analogues. The method comprises the following steps: encoding genes of the antibodies or the antibody analogues are guided into the yeast Kluyveromyces to obtain recombinant bacteria; the antibody analogues are fusion proteins formed by Fc fragments of the antibodies and proteins or protein subunits; the encoding genes of the antibodies are heavy chain and light chain encoding genes of the antibodies. The recombinant yeast Kluyveromyces for expressing antibodies or antibody analogues can be cultured to produce complete antibodies or antibody analogues. The invention uses the yeast Kluyveromyces to prepare the antibodies or antibody analogues to preliminarily overcome the difficulties of difficult antibody production, high purity and large quantity requirements for products and provide good application prospects.

The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as an active ingredient, and methods for treating inflammatory disease or autoimmune diseases with the pharmaceutical composition. Novel biphenyl derivatives according to the present invention promote the phagocytosis of macrophages and inhibit the chemotaxis to exhibit excellent inflammation terminating and anti-inflammatory effects and thus can be effectively used as therapeutic agents for inflammatory diseases or autoimmune diseases.

Techniques for treating a tumor and vaccinating against cancer are described. The techniques include treating the tumor by positioning electrodes over an interface between the tumor and non-tumor tissue and applying sub-microsecond pulsed electric fields. The positioning is facilitated by an imaginary contour line of a threshold value of the electric field. In an example, the imaginary contour line is overlaid over images that include the tumor such that the electrodes are properly positioned over the tumor. The techniques also include vaccinating against cancer by passing sub-microsecond pulsed electric fields through tumor cells of a subject sufficient to cause the tumor cells to express calreticulin on surface membranes. The tumor cells are extracted and introduced with the expressed calreticulin into the subject or another subject, thereby providing a vaccination.

The invention discloses a two-block double-sensitive camptothecin polymer prodrug taking benzeneboronic ester as a connecting unit and a preparation method of the two-block double-sensitive camptothecin polymer prodrug. The two-block double-sensitive camptothecin polymer prodrug takes benzeneboronic catechol ester (BC) as the connecting unit, polyethylene glycol-polyglutamate disulfide ethanol camptothecin two-block polymer (PEG-BC-PGlu-ss-CPT) is synthesized, thereby constructing a self-assembly prodrug nano micelle, namely PEG-BC@PGlu-ss-CPT; PEG-BC is taken as a macroinitiator an initiatorto perform an open-loop polymerization reaction on a reduction-sensitive camptothecin monomer to obtain the two-block double-sensitive camptothecin polymer prodrug PEG-BC-PGlu-ss-CPT taking the benzeneboronic ester as the connecting unit. The prepared prodrug micelle can improve the solubility of camptothecin and improve the stability of a camptothecin lactone ring so as to overcome the limitationof camptothecin clinical treatment, and the prodrug micelle has a good drug release property and dual sensitive properties of acid sensitivity and reduction sensitivity.

The invention relates to a preparation method of γ-PGA hydrogel loaded with Au nanoparticles, comprising: adding PEI solution to activated mPEG-COOH solution to obtain PEI·NH 2 -mPEG, add chloroauric acid after being dissolved in ultrapure water, stir, add sodium borohydride aqueous solution, get (Au 0 ) 200 -PEI·NH 2 -mPEG; Add sodium bicarbonate to the activated γ-PGA solution, then add it to the DCM solution of AOT to get a W / O emulsion, add it to the PVA solution to get a W / O / W polymer emulsion; ( Au 0 ) 200 -PEI·NH 2 - Add the ultrapure aqueous solution of mPEG into the polymer emulsion drop by drop, and stir to obtain it. The invention has simple process and low cost; the prepared hydrocoagulation has good X-ray attenuation performance, remarkable imaging effect, good water solubility, colloidal stability, cell compatibility and biocompatibility.

The invention discloses a nicotinamide mononucleotide and herbal extract microcapsule with limited component proportion. The capsule can maximize the immune resistance function. The preparation devicecomprises a container for accommodating nicotinamide mononucleotide, herbal active extract and an extraction solvent, and a return pipe, wherein the return pipe is provided with a feeding pipe, a delivery pipe and a connecting pipe; and a necking assembly is arranged in the connecting pipe. The device also comprises an ultrasonic assembly arranged in the connecting pipe, which can generate ultrasonic waves to quickly and uniformly mix the nicotinamide mononucleotide and herbal active extract in the mixed solution. The novel preparation process is utilized to uniformly fuse the herbal plant concentrated solution and excipient / emulsifier by a microencapsulation technique, thereby being different from the traditional excipient or emulsifier which is only coated on the outer layer, enhancingthe functional component proportion, lowering the excipient content and increasing the bioavailability requirements of the nicotinamide mononucleotide and herbal active extract.

The invention relates to the technical field of livestock breeding, and in particular, discloses a polypeptide composition, a composition for improving the livestock and poultry immune function, and a preparation method of the composition for improving the livestock and poultry immune function. The polypeptide composition is prepared from bursin peptide, thymosin and a transfer factor according to the mass ratio of (0.5-5):(0.5-5):(0.5-5). The composition for improving the livestock and poultry immune function is prepared from the following raw materials in parts by weight: 20-30 parts of B vitamins, 20-30 parts of vitamin C, 10-20 parts of the polypeptide composition, 10-15 parts of taurine, 1-2 parts of an anti-caking agent, and 40-50 parts of porous starch. The polypeptide composition and the composition can both be used as feed additives, or as pharmaceutical preparations to be added in drinking water, or as pharmaceutical preparations used for injection, have good prevention and control effects on swine fever, foot-and-mouth disease, circovirus, piglet diarrhea, Newcastle disease, mild type flu, duck liver virus disease and the like, reduce the use of antibiotics, reduce the occurrence of epidemic diseases, reduce mortality rate, and improve the immunity.

The invention discloses a dendritic cell inducer and a preparation method and application thereof. The dendritic cell inducer is a compound of nervous peptide and graphene oxide, and dendritic cells can be induced into tolerant dendritic cells. Compared with other immunomodulators such as rapamycin and cocktail of cytokines, the compound is suitable for inducing the tolerant dendritic cells, has the advantages of simplicity in preparation, high stability and low price, and can be used for treating autoimmune diseases such as acute-graft-versus-host diseases, rheumatic arthritis and antoimmunediabetes.